Atesidorsen

View Clinical trials for Atesidorsen Get Atesidorsen Patent Info for Free

ATL1103 is a second generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production predominantly in the liver, ATL1103 in turn reduces levels of the hormone insulin like growth factor (IGF-I) in the blood (serum). There are a number of diseases that are associated with excess GH and IGF-I. These diseases include acromegaly, an abnormal growth disorder of organs, face, hands and feet, diabetic retinopathy, a common disease of the eye and a major cause of blindness, diabetic nephropathy, a common disease of the kidney and major cause of kidney failure, and some forms of cancer.

Inn NameAtesidorsen
Usan NameAtesidorsen
Lab CodesCOR-004, ATL-1103, ISIS-227452
Chemical NameDNA, d(P-thio)((2'-O-(2-methoxyethyl))m5rU-(2'-O-(2-methoxyethyl))m5rC-(2'-O-(2-methoxyethyl))rA-(2'-O-(2-methoxyethyl))rG-(2'-O-(2-methoxyethyl))rG-G-m5C-A-T-T-m5C-T-T-T-m5C-(2'-O-(2-methoxyethyl))m5rC-(2'-O-(2-methoxyethyl))rA-(2'-O-(2-methoxyethyl))m5rU-(2'-O-(2-methoxyethyl))m5rU-(2'-O-(2-methoxyethyl))m5rC)
Alternate Name(all-P-ambo)-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidine
Sequence(3'-5')(P-thio)(Tmoe-mCmoe-Amoe-Gmoe-Gmoe-dG-mdC-dA-dT-dT-mdC-dT-dT-dT-mdC-mCmoe-Amoe-Tmoe-Tmoe-mCmoe)
Legend: d (as prefix) = 2'-deoxy
m (as prefix) = 5-methyl
moe (as suffix) = 2'-O-(2-methoxyethyl)
Chemical StructureAtesidorsen.png
Molecular FormulaC230H321N64O124P19S19
Cas Registry Number872063-57-5
New Molecular EntityYes
OriginatorIsis Pharmaceuticals
DeveloperAntisense Therapeutics Limited, Strongbridge Biopharma plc
Mechanism Of ActionSomatotropin receptor antagonist
Who Atc CodesA10X (Other Drugs Used in Diabetes)
H01C-B (Somatostatin and analogues)
L01 (Antineoplastic Agents)
S01X (Other Ophthalmologicals)
Ephmra CodesA10X (Other Drugs Used in Diabetes)
H1C2 (Antigrowth hormones)
L1 (Antineoplastics)
S1X (Other Ophthalmologicals)
IndicationTreatment of acromegaly

Free counters!